RT Journal Article
SR Electronic
T1 Hodgkin's lymphoma: the pathologist's viewpoint
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 162
OP 176
VO 55
IS 3
A1 Pileri, S A
A1 Ascani, S
A1 Leoncini, L
A1 Sabattini, E
A1 Zinzani, P L
A1 Piccaluga, P P
A1 Pileri, A
A1 Giunti, M
A1 Falini, B
A1 Bolis, G B
A1 Stein, H
YR 2002
UL http://jcp.bmj.com/content/55/3/162.abstract
AB Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B cell derivation of the tumour in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognises a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (CHL), reflecting the differences in clinical presentation and behaviour, morphology, phenotype, and molecular features. CHL has been classified into four subtypes: lymphocyte rich, nodular sclerosing, with mixed cellularity, and lymphocyte depleted. The borders between CHL and anaplastic large cell lymphoma have become sharper, whereas those between LP-HL and T cell rich B cell lymphoma remain ill defined. Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied.